Background: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease. Methods: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IV aggressive , those with < 5 CTCs as Stage IV indolent. Survival was analyzed using Kaplan-Meier curves and the log rank test. Results: For all patients, Stage IV indolent patients had longer median overall survival than those with Stage IV aggressive (36.3 months vs. 16.0 months, P < 0.0001) and similarly for de novo MBC patients (41.4 months Stage IV indolent vs. 18.7 months Stage IV aggressive , p < 0.0001). Moreover, patients with Stage IV indolent disease had significantly longer overall survival across all disease subtypes compared to the aggressive cohort: hormone receptor-positive (44 months vs. 17.3 months, P < 0.0001), HER2-positive (36.7 months vs. 20.4 months, P < 0.0001), and triple negative (23.8 months vs. 9.0 months, P < 0.0001). Similar results were obtained regardless of prior treatment or disease location. Conclusions: We confirm the identification of two subgroups of MBC, Stage IV indolent and Stage IV aggressive , independent of clinical and molecular variables. Thus, CTC count should be considered an important tool for staging of advanced disease and for disease stratification in prospective clinical trials.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper / Cristofanilli, M.; Pierga, J. -Y.; Reuben, J.; Rademaker, A.; Davis, A. A.; Peeters, D. J.; Fehm, T.; Nole, F.; Gisbert-Criado, R.; Mavroudis, D.; Grisanti, S.; Giuliano, M.; Garcia-Saenz, J. A.; Stebbing, J.; Caldas, C.; Gazzaniga, P.; Manso, L.; Zamarchi, R.; de Lascoiti, A. F.; De Mattos-Arruda, L.; Ignatiadis, M.; Cabel, L.; van Laere, S. J.; Meier-Stiegen, F.; Sandri, M. -T.; Vidal-Martinez, J.; Politaki, E.; Consoli, F.; Generali, D.; Cappelletti, M. R.; Diaz-Rubio, E.; Krell, J.; Dawson, S. -J.; Raimondi, C.; Rutten, A.; Janni, W.; Munzone, E.; Caranana, V.; Agelaki, S.; Almici, C.; Dirix, L.; Solomayer, E. -F.; Zorzino, L.; Darrigues, L.; Reis-Filho, J. S.; Gerratana, L.; Michiels, S.; Bidard, F. -C.; Pantel, K.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 134:(2019), pp. 39-45. [10.1016/j.critrevonc.2018.12.004]

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

Gazzaniga P.;
2019

Abstract

Background: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease. Methods: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IV aggressive , those with < 5 CTCs as Stage IV indolent. Survival was analyzed using Kaplan-Meier curves and the log rank test. Results: For all patients, Stage IV indolent patients had longer median overall survival than those with Stage IV aggressive (36.3 months vs. 16.0 months, P < 0.0001) and similarly for de novo MBC patients (41.4 months Stage IV indolent vs. 18.7 months Stage IV aggressive , p < 0.0001). Moreover, patients with Stage IV indolent disease had significantly longer overall survival across all disease subtypes compared to the aggressive cohort: hormone receptor-positive (44 months vs. 17.3 months, P < 0.0001), HER2-positive (36.7 months vs. 20.4 months, P < 0.0001), and triple negative (23.8 months vs. 9.0 months, P < 0.0001). Similar results were obtained regardless of prior treatment or disease location. Conclusions: We confirm the identification of two subgroups of MBC, Stage IV indolent and Stage IV aggressive , independent of clinical and molecular variables. Thus, CTC count should be considered an important tool for staging of advanced disease and for disease stratification in prospective clinical trials.
2019
Biomarker; Circulating tumor cells; CTCs; MBC; Metastatic breast cancer; Survival; Biomarkers, Tumor; Breast Neoplasms; Consensus; Expert Testimony; Female; Humans; International Agencies; Neoplasm Staging; Neoplastic Cells, Circulating; Patient Selection
01 Pubblicazione su rivista::01a Articolo in rivista
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper / Cristofanilli, M.; Pierga, J. -Y.; Reuben, J.; Rademaker, A.; Davis, A. A.; Peeters, D. J.; Fehm, T.; Nole, F.; Gisbert-Criado, R.; Mavroudis, D.; Grisanti, S.; Giuliano, M.; Garcia-Saenz, J. A.; Stebbing, J.; Caldas, C.; Gazzaniga, P.; Manso, L.; Zamarchi, R.; de Lascoiti, A. F.; De Mattos-Arruda, L.; Ignatiadis, M.; Cabel, L.; van Laere, S. J.; Meier-Stiegen, F.; Sandri, M. -T.; Vidal-Martinez, J.; Politaki, E.; Consoli, F.; Generali, D.; Cappelletti, M. R.; Diaz-Rubio, E.; Krell, J.; Dawson, S. -J.; Raimondi, C.; Rutten, A.; Janni, W.; Munzone, E.; Caranana, V.; Agelaki, S.; Almici, C.; Dirix, L.; Solomayer, E. -F.; Zorzino, L.; Darrigues, L.; Reis-Filho, J. S.; Gerratana, L.; Michiels, S.; Bidard, F. -C.; Pantel, K.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 134:(2019), pp. 39-45. [10.1016/j.critrevonc.2018.12.004]
File allegati a questo prodotto
File Dimensione Formato  
Cristofanilli_Clinical-use_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 910.92 kB
Formato Adobe PDF
910.92 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1503532
Citazioni
  • ???jsp.display-item.citation.pmc??? 123
  • Scopus 199
  • ???jsp.display-item.citation.isi??? 179
social impact